Covidien Introduces New Barrx™ RF Ablation Catheter for Treating Barrett's Esophagus

Before you go, we thought you'd like these...
Before you go close icon

Covidien Introduces New Barrx™ RF Ablation Catheter for Treating Barrett's Esophagus

Barrx™ Channel RFA Endoscopic Catheter eliminates need for multiple endoscope introductions; also offers enhanced visualization

SUNNYVALE, Calif.--(BUSINESS WIRE)-- Covidien (NYS: COV) , a leading global provider of healthcare products, announced the expansion of its portfolio of radiofrequency ablation (RFA) catheters with the launch of the Barrx™ Channel RFA Endoscopic Catheter for treating Barrett's esophagus and certain gastrointestinal bleeding disorders1. Left untreated, Barrett's esophagus, a precancerous condition of the esophageal lining, can lead to life-threatening cancer of the esophagus.

The Barrx line of RFA catheters is based on Covidien's proprietary technology that carefully controls the amount of RF energy delivered to remove diseased tissue, thereby allowing the growth of healthy tissue. Endoscopic surgeons and gastroenterologists can shorten procedure time with the new Channel RFA device, as this patient-centric design allows for fewer endoscope introductions and removals (compared to other Barrx catheters). The innovative technology in the Channel catheter enables a 7.5mm wide electrode to easily pass through a 2.8mm diameter endoscope working channel.

"Covidien continues to offer patients and physicians a solution to address Barrett's esophagus," said Vafa Jamali, Vice President and General Manager, GI Solutions, Covidien. "The newest addition to the Barrx portfolio is designed to simplify the procedure by delivering our proven RF technology through the working channel of the endoscope."

Other features and benefits of the new device include a transparent ablation electrode for enhanced visualization and a unique rotatable shaft design that provides additional control and maneuverability. The Barrx Channel RFA Endoscopic Catheter is available in the United States and Europe.

For more information about Covidien's Barrx solutions, RFA eradication therapy and Barrett's esophagus, please visit

About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading products in medical devices and supplies. With 2012 revenue of $9.9 billion, Covidien has 38,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit to learn more about our business.

1 The Barrx Channel RFA Endoscopic Catheter (used with the Barrx™ Flex RFA Energy Generator) is indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract, including, but not limited to, the esophagus. Indications include esophageal ulcers, Mallory-Weiss tears, arteriovenous malformations, angiomata, Barrett's esophagus, Dieulafoy lesions, angiodysplasia, Gastric antral vascular ectasia (GAVE) and radiation proctitis (RP).


John Jordan, 508-452-4891
Manager, Communications
Surgical Solutions
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
Marguerite Copel, 203-821-4720
Vice President, Communications
Surgical Solutions
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations

KEYWORDS:   United States  North America  California


The article Covidien Introduces New Barrx™ RF Ablation Catheter for Treating Barrett's Esophagus originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading